Biotech and Pharma Companies Pause Gene Therapy Trials Following Patient Deaths
TL;DR Summary
Sarepta Therapeutics has paused its gene therapy trial after the deaths of two patients from acute liver failure, raising concerns about the safety of Elevidys, a treatment for Duchenne muscular dystrophy, which was approved under accelerated pathways despite safety warnings.
Topics:business#duchenne-muscular-dystrophy#elevidys#gene-therapy#health#patient-safety#sarepta-therapeutics
- Biotech pauses trial after second patient death linked to gene therapy The Washington Post
- Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne Sarepta Therapeutics
- UPDATE: Second Patient Dies After Receiving Sarepta’s DMD Gene Therapy Elevidys BioSpace
- Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures WSJ
- After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry statnews.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 4 min read
Condensed
95%
770 → 40 words
Want the full story? Read the original article
Read on The Washington Post